| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Reference and Education > Paranormal > Bigfoot Does Cameos, Not Recurring Roles |
|
Advice Pool - Bigfoot Does Cameos, Not Recurring Roles
The more you study the Bigfoot phenomenon, the more you bump into events and circumsta According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product nces that warp the boundaries we've established. UFOs, missing time, disappearing Bigf ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ots...none of these jive with the just-an-ape theory. But one seemingly innocuous phen lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. menon has incited more debate than one would expect. Witnesses who claim repeated enc here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe unters with Bigfoots. I've heard various labels attached to these witnesses. On her w d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro bsite, Autumn Williams calls them long-term witnesses. Loren Coleman calls them Bigfoo ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc contactees (a reference to the UFO contactee movement of the 1950s & 1960s). Why can' easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi we simply call them witnesses? The need to label these witnesses seems silly. UFO wi nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically nesses who have more than one encounter rarely get labeled with a special designation. and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ The UFO contactees were people who claimed to have had face-to-face encounters with uf ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi nauts on spaceships—like George Adamski, the most famous contactee. Usually, the witne ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a s returned from the trip with a peaceful message or a benign warning for humanity to c dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ean up its act. Some Bigfoot witnesses claim to have had psychic communication from t cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin e creatures, with messages which relate themes similar to the what UFO contactees repo tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ted. Most repeat witnesses have no message for humanity. They have simply met Bigfoots t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel on more than one occasion. When a witness starts to recount multiple sightings, why mu ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust t we stamp a name on that person's forehead? Instead, we should try to figure out why y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ertain people have multiple encounters. Of course, before we can do that, we must fir . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de t apply the same credibility test to these witnesses as we use for incidental witnesse elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip . We must treat them with respect, rather than snickering at them. ©2007 Lisa A. Shie tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Web Design do it Correctly and Benefit - Do it Wrong and Flush Away your Cash Online Dating – Why Golfers Have So Many Successful Singles Groups
|